Effect of vitaminD3 or 25(OH)D3 Fortified Dairy on Vitmain D Status and CVD Risk Markers

Overview

This study aims to compare the acute effect of consuming milk and butter fortified with either vitamin D3 or 25 (OH) D3 on serum/plasma vitamin D status in humans. In addition, the effect of vitamin D3 or 25 (OH) D3 in milk and butter on certain CVD risk markers and cognitive function will be examined.

Full Title of Study: “Fortification of Milk and Butter With Either vitaminD3 or 25(OH)D3: The Effect on Vitamin D Status and Cardiovascular Disease Risk Markers in Humans”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2015

Detailed Description

There is mounting evidence to show that vitamin D deficiency may increase the risk of many common and serious diseases, including osteoporosis, cardiovascular disease, some cancers and type 1 diabetes (Holick and Chen, 2008). Hypovitaminosis D is now prevalent in the UK general population. Due to diet and lifestyle changes and the use of sun block products most people do not endogenously synthesise sufficient vitamin D from sunlight exposure (Hyppönen and Power, 2007). Therefore, vitamin D intakes from dietary sources have become very important, however this is limited as there are only a few foods naturally rich in vitamin D. Some countries (e.g. USA, Canada) fortify milk with vitamin D which results in milk being the major contributor to vitamin D intake. Vitamin D3 is the most common form used for the fortification of currently fortified foods. However, there is now some evidence that 25(OH)D3 can increase vitamin D status of humans more effectively than vitamin D3 (Bischoff-Ferrari et al, 2012; Cashman et al, 2012). To our knowledge, very few human intervention studies have compared the efficacy of 25(OH)D3 versus vitamin D3 to increase vitamin D status, and there has been no acute human study to examine the effect of the both forms of vitamin D fortified dairy products on vitamin D status in humans.

Interventions

  • Dietary Supplement: vitamin D3
    • Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
  • Dietary Supplement: 25(OH) D3
    • Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
  • Dietary Supplement: Control
    • Subjects are asked to consume a breakfast without vitamin D

Arms, Groups and Cohorts

  • Experimental: breakfast rich in vitamin D3
    • subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
  • Experimental: breakfast rich in 25(OH) D3
    • subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
  • Placebo Comparator: Control
    • subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline in the concentrations of vitamin D3, 25(OH)D3, 1, 25(OH)2D3 of the blood
    • Time Frame: Acute study: measured at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 min and 24 hour
  • Change from baseline in the concentrations of vitamin D3 and 25(OH)D3 of the chylomicron
    • Time Frame: Acute study: measured at 0 (baseline), 3, 6, 8 hour

Secondary Measures

  • change from baseline in vascular reactivity measured by Endo-PAT
    • Time Frame: Acute study: measured at 0 (baseline) and the 24 hour
  • change from baseline in vascular reactivity measured by digital volume pulse (DVP)
    • Time Frame: Acute study: measured at 0 (baseline), 120, 240, 360, 480 min and 24 hour
  • change from baseline in plasma lipids (primarily triacylglycerol, apolipoprotein B, apolipoprotein B-48, apolipoprotien B-100, total-cholesterol, HDL-cholesterol, non-esterified fatty acids)
    • Time Frame: from 0 to 24 hour, but different measured time points for diferent lipids
    • non-esterified fatty acids, apolipoprotein B, apolipoprotein B-48, apolipoprotein B-100 are taken at 0(baseline), 60, 120, 240, 360, 480 min and 24 hour; triacylglycerol is taken at 0, 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 min and 24 hour; total and HDL-cholesterol only be measured at 0 (baseline)
  • change from baseline in markers of insulin resistance (glucose and insulin)
    • Time Frame: Acute study: measured at 0, 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 min and 24 hour
  • change from baseline in nitric oxide
    • Time Frame: Acute study: measured at 0, 60, 120, 240, 360, 480 min and 24 hour
  • change from baseline in inflammatory markers (tumor necrosis factor alpha, C-reactive protein and interleukin 6) of the blood
    • Time Frame: Acute study: measured at 0, 60, 120, 240, 360, 480 min and 24 hour
  • change from baseline in blood pressure
    • Time Frame: Acute study: measured at 0, 120, 240, 360, 480 min and 24 hour
  • change from baseline in cognitive test
    • Time Frame: Acute study: measured at 0, 480 min and 24 hour
    • Trail Making Test (TMT) will be used for cognitive test, which can provides information on visual search, scanning, speed of processing, mental flexibility, and executive function. The TMT consists of two parts: TMT-A requires a participant to draw lines sequentially connecting 25 encircled numbers distributed on a computer screen, whilst in the TMT-B the participant must alternate between numbers and letters (e.g., 1, A, 2, B, 3, C, etc.). TMT-A and TMT-B will be administered using a laptop computer. Results from this two tasks reported as the number of seconds required to complete the task (completion time). The longer time spent reveal greater cognitive impairment.”

Participating in This Clinical Trial

Inclusion Criteria

  • BMI: 20-35 kg/m2 – Glucose <7 mmol/l (not diagnosed with diabetes) – Total cholesterol <7 mmol/l – TAG <4 mmol/l – Serum 25(OH)D3 ≤50 nmol/L – Normal liver and kidney function – Haemoglobin: adult male >125 g/L Exclusion Criteria:

  • Milk allergy/intolerance or lactose intolerance – Cardiovascular, renal, gastrointestinal, respiratory, endocrine disease or cancer – Use of nutritional supplements, particularly those containing vitamin D – Outdoor workers and use of tanning beds – Overseas holidays two months before or during study period

Gender Eligibility: Male

Minimum Age: 30 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Reading
  • Provider of Information About this Clinical Study
    • Principal Investigator: Julie Lovegrove, Professor Julie Lovegrove – University of Reading

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.